What this study looked at
Alpha-mannosidosis (AM) is a rare inherited disorder in which a missing lysosomal enzyme allows mannose-rich sugar chains to build up in the body. Velmanase alfa is the first enzyme replacement therapy for its non-neurological symptoms. This pooled analysis of 33 treated patients explored whether a person's MAN2B1 genotype was linked to the development of anti-drug antibodies and infusion-related reactions, and whether those antibodies affected how well treatment worked.
Key takeaways
- Ten of the 33 patients tested positive for anti-drug antibodies, and these appeared more often in the G1 and G2 genotype subgroups.
- The few patients with relatively high antibody levels experienced only mild to moderate infusion-related reactions that were well managed.
- Reductions in serum oligosaccharides and clinical outcomes on the walking and stair-climbing tests were broadly similar whether or not patients had developed antibodies.
Why it matters
The findings suggest that, although genotype may influence antibody development, these antibodies have little effect on how well velmanase alfa works for most patients — reassuring for clinicians and families weighing up treatment.
